Stock Groups

Regeneron Gains on Claims its Antibody Cocktail Prevents Covid -Breaking

by Mike Robinson

[ad_1]

© Reuters

By Dhirendra Tripathi

Investing.com – Regeneron Pharmaceuticals stock (NASDAQ:) rose 1% on Monday after the company said a single dose of its antibody cocktail significantly reduces the risk of contracting Covid-19.

The results of a late stage trial proved that Regen-Cov is an antibody treatment which can provide lasting immunity against infection. Myron Cohn, the director of the monoclonal antibodies efforts of the U.S. National Institutes of Health sponsored Covid Prevention Network, stated, “The potential of antibody therapy to provide long-lasting immunity towards the infection,”

Participants could choose to be vaccinated after the completion of month 1 (primary efficacy treatment) in the trial.

Regen-Cov has been authorized by the U.S. for treatment of people at risk from serious Covid-19 consequences. This includes those already infected, but not in hospital. In the U.S., it is not permitted to be used as a replacement for vaccine against Covid.

Regeneron and Roche are collaborating to increase the global supply for the antibody cocktail. Roche will be responsible for developing the product outside of the United States.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]